CTLA4 and Miyoshi myopathy: Anti-CTLA-4 treatment prior to BRAF inhibition has also been associated with a significant survival benefit over the reverse sequence in BRAF-mutated MM (n = 45, 14.5 mo vs. 9.9 mo), though median OS varied widely among the BRAF-ipilimumab cohort in this study depending on who did or did not complete the ipilimumab treatment protocol (12.7 vs. 1.2 mo, p < 0.001) [42].